Biosimilar Trial for Plaque Psoriasis (36 Weeks)

Adults aged 18-75 years old with moderate to severe plaque psoriasis (with or without psoriatic arthritis) for at least 6 months, may qualify to participate. Individuals must have stable disease for at least 2 months, with psoriatic involvement of 10% or more body surface area. There must also be no known history of latent or active tuberculosis (TB); testing will occur at screening.

Participants will be part of one of two groups: the continued-use group (receiving adalimumab) OR the switching group (receiving investigational medication (active study drug) and adalimumab), via subcutaneous injection. Study medication and study-related assessments will be provided at no cost. Reimbursement for reasonable study-related expenses will also be provided.

Study participation will last about 36 weeks and involve about 23 visits to the study centre.

Call the study centre near you, or register now.

Learn more about
Psoriasis
Register Now!

Participating Locations

AR

  • Sorry no locations are available in this country.

AU

  • Sorry no locations are available in this country.

CL

  • Sorry no locations are available in this country.

MX

  • Sorry no locations are available in this country.

Register for
Active Studies!

Register

All information about you will be kept confidential.

If there are no active studies for your condition, we will keep your information and contact you when a new study starts in your area.

By registering you are consenting to the terms and conditions of our privacy policy.

Find the clinic near you:

Why Take Part In a Clinical Study?

Regulatory agencies like Health Canada, Australia's Therapeutic Goods Administration and the FDA require that Clinical Research Trials be conducted in order to develop new treatments, preventions and devices for diseases or conditions. Clinical Research Trials are also referred to as Clinical Studies or Clinical Trials. read more